Stifel Nicolaus Initiates Coverage on Palisade Bio (NASDAQ:PALI)

Investment analysts at Stifel Nicolaus started coverage on shares of Palisade Bio (NASDAQ:PALI) in a report released on Wednesday, Marketbeat reports. The brokerage set a “buy” rating and a $5.00 price target on the stock. Stifel Nicolaus’ target price points to a potential upside of 170.27% from the company’s current price.

A number of other analysts have also commented on PALI. Clear Str upgraded Palisade Bio to a “strong-buy” rating in a research report on Monday, December 29th. Piper Sandler initiated coverage on shares of Palisade Bio in a research note on Monday, December 29th. They issued an “overweight” rating and a $25.00 target price on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of Palisade Bio from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Finally, B. Riley Financial started coverage on shares of Palisade Bio in a report on Friday, January 9th. They issued a “buy” rating and a $7.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $13.25.

Palisade Bio Price Performance

Shares of PALI stock opened at $1.85 on Wednesday. The stock’s fifty day simple moving average is $1.87 and its 200 day simple moving average is $1.57. Palisade Bio has a one year low of $0.53 and a one year high of $2.64. The firm has a market cap of $275.65 million, a price-to-earnings ratio of -0.87 and a beta of 1.58.

Institutional Trading of Palisade Bio

A number of large investors have recently bought and sold shares of the business. Perceptive Advisors LLC bought a new position in shares of Palisade Bio in the fourth quarter valued at $28,318,000. Commodore Capital LP bought a new position in shares of Palisade Bio in the 4th quarter valued at about $26,896,000. Janus Henderson Group PLC bought a new position in shares of Palisade Bio in the 4th quarter valued at about $24,822,000. RA Capital Management L.P. acquired a new position in shares of Palisade Bio during the 4th quarter worth about $16,742,000. Finally, Eversept Partners LP bought a new stake in shares of Palisade Bio in the 4th quarter valued at about $12,670,000. 11.79% of the stock is owned by institutional investors.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.